Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes

Human Gene Therapy

Volumn 15, Issue 10, 2004, Pages 995-1002

  Martin Duque, Pilar ^a,b   Jezzard, Sarah ^a   Kaftansis, Lambrini ^a   Vassaux, Georges ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GLOBIN; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; THYMIDINE KINASE;

ARTICLE; ERBB2 GENE; GENE; GENE CASSETTE; GENE TARGETING; HERPES SIMPLEX VIRUS; HSVTK GENE; HUMAN; HUMAN CELL; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENE;

ADENOVIRIDAE; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL SURVIVAL; CHICKENS; CHROMATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLOBINS; GREEN FLUORESCENT PROTEINS; MODELS, GENETIC; PLASMIDS; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; THYMIDINE KINASE; TRANSCRIPTION, GENETIC;

ADENOVIRIDAE; BOVINAE; GALLUS GALLUS; SIMPLEXVIRUS;

EID: 1842717937     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2004.15.995     Document Type: Article

References (22)

1. BELL, A.C., WEST, A.G., and FELSENFELD, G. (1999). The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98, 387-396.
2. BUVOLI, M., LANGER, S.J., BIALIK, S., and LEINWAND, L.A. (2002). Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors. Gene Ther. 9, 227-231.
3. CAILLEAU, R., YOUNG, R., OLIVE, M., and REEVES, W.J., Jr. (1974). Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53, 661-674.
4. CHUNG, J.H., BELL, A.C., and FELSENFELD, G. (1997). Characterisation of the chicken β-globin insulator. Proc. Natl. Acad. Sci. U.S.A. 94, 575-580.
5. GRAHAM, F.L., and PREVEC, L. (1992). Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20, 363-390.
6. GROOT-WASSINK, T., ABOAGYE, E.O., GLASER, M., LEMOINE, N.R., and VASSAUX, G. (2002). Adenovirus biodistribution and non-invasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. 13, 1723-1735.
7. HASEGAWA, K., and NAKATSUJI, N. (2002). Insulators prevent transcriptional interference between two promoters in a double gene construct for transgenesis. FEBS Lett. 520, 47-52.
8. HATFIELD, L., and HEARING, P. (1991). Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for the viral growth in vivo. Virology 184, 265-276.
9. HE, T.C., ZHOU, S., DA COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenovirus. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
10. HEARING, P., and SHENK, T. (1983). The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell 33, 695-703.
11. HEARING, P., and SHENK, T. (1986). The adenovirus type 5 enhancer contains two functionally distinct domains: One is specific for E1A and the other modulates all early units in cis. Cell 45, 229-236.
12. LAHERTY, R.F., BALCAVAGE, W.X., GOFF, C., ALVAGER, T., GHOSH, S., GEIB, R.W., KING, M., and PERSONETT, D. (1990). HBL-100 cells do not secrete casein and lack prolactin and estradiol receptors. In Vitro Cell. Dev. Biol. 26, 933-935.
13. METZGAR, R.S., GAILLARD, M.T., LEVINE, S.J., TUCK, F.L., BOSSEN, E.H., and BOROWITZ, M.J. (1982). Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 42, 601-608.
14. NETTELBECK, D.M., JEROME, V., and MULLER, R. (2000). Gene therapy: Designer promoters for tumour targeting. Trends Genet. 16, 174-181.
15. PROUDFOOT, N.J. (1986). Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation. Nature 322, 562-565.
16. RING, C.J.A., HARRIS, J.D., HURST, H.C., and LEMOINE, N.R. (1996). Suicide expression in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 3, 1094-1103.
17. RUBINCHIK, S., LOWE, S., JIA, Z., NORRIS, J., and DONG, J. (2001a). Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters. Gene Ther. 8, 247-253.
18. RUBINCHIK, S., WANG, D., YU, H., FAN, F., LUO, J., NORRIS, J., and DONG, J.Y. (2001b). A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol. Ther. 4, 416-426.
19. SHI, Q., WANG, Y., and WORTON, D. (1997). Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum. Gene Ther. 8, 403-410.
20. STEINWAERDER, D.S., and LIEBER, A. (2000). Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. 7, 556-567.
21. VASSAUX, G., HURST, H.C., and LEMOINE, N.R. (1999). Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 6, 1192-1197.
22. YAMAMOTO, M., DAVYDOVA, J., TAKAYAMA, K., ALEMANY, R., and CURIEL, D.T. (2003). Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with E1 deleted. J. Virol. 77, 1633-1637.